Lipocine (NASDAQ:LPCN) Shares Pass Above 50-Day Moving Average – Time to Sell?

Lipocine Inc. (NASDAQ:LPCN) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.31 and traded as high as $2.37. Lipocine shares last traded at $2.29, with a volume of 30,358 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LPCN shares. HC Wainwright reissued a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Weiss Ratings downgraded Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. Finally, Wall Street Zen lowered Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Price Performance

The company’s 50-day moving average price is $2.31 and its 200-day moving average price is $5.35. The company has a market cap of $18.88 million, a P/E ratio of -1.22 and a beta of 0.44.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. On average, equities research analysts predict that Lipocine Inc. will post -1.91 EPS for the current year.

Institutional Trading of Lipocine

Several hedge funds and other institutional investors have recently modified their holdings of LPCN. Renaissance Technologies LLC lifted its holdings in shares of Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after buying an additional 1,374 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after buying an additional 6,982 shares in the last quarter. Jane Street Group LLC acquired a new stake in Lipocine in the 4th quarter valued at approximately $85,000. Finally, Citadel Advisors LLC acquired a new stake in Lipocine in the 3rd quarter valued at approximately $41,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.